Efficacy and immunogenicity following dengue virus-1 human challenge after a tetravalent prime-boost dengue vaccine regimen: an open-label, phase 1 trialKirsten E. Lyke, Robert Edelman, Michael K. McCracken et al.|The Lancet Infectious Diseases|2024Cited by 24